Metsera, weight-loss drug developer, reported wider loss in paperwork for U.S. IPO.

From Investing.com: 2025-01-10 17:20:39

Metsera, a weight-loss drug developer backed by ARCH Venture Partners, reported a wider loss in its paperwork for a U.S. IPO. The terms of the IPO were not disclosed in the filing. The company, founded in 2022, revealed a net loss of $156.26 million in the first nine months of 2024, compared to $34.18 million in the same period in 2023.

Metsera plans to list its shares on the Nasdaq Global Market under the ticker symbol “MTSR”. BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor will serve as underwriters for the offering. Strong equity markets and hopes of a friendlier regulatory environment under the incoming Trump administration have encouraged companies to list their shares.



Read more at Investing.com: Weight-loss drug developer Metsera reveals wider loss in US IPO filing By Reuters